Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Scholar Rock Holding (SRRK – Research Report), Replimune Group (REPL – Research Report) and Precision BioSciences (DTIL – Research Report).
Scholar Rock Holding (SRRK)
BMO Capital analyst Etzer Darout maintained a Buy rating on Scholar Rock Holding yesterday and set a price target of $29.00. The company’s shares closed last Tuesday at $12.35, close to its 52-week high of $13.15.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
Currently, the analyst consensus on Scholar Rock Holding is a Strong Buy with an average price target of $25.00, which is an 113.7% upside from current levels. In a report issued on October 24, Jefferies also upgraded the stock to Buy with a $20.00 price target.
See today’s best-performing stocks on TipRanks >>
Replimune Group (REPL)
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Replimune Group, with a price target of $70.00. The company’s shares closed last Tuesday at $10.83, close to its 52-week low of $10.79.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
Replimune Group has an analyst consensus of Strong Buy, with a price target consensus of $57.33, a 354.6% upside from current levels. In a report issued on November 4, Leerink Partners also reiterated a Buy rating on the stock.
Precision BioSciences (DTIL)
BMO Capital analyst Kostas Biliouris reiterated a Hold rating on Precision BioSciences yesterday and set a price target of $3.00. The company’s shares closed last Tuesday at $0.39, close to its 52-week low of $0.28.
According to TipRanks.com, Biliouris is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Precision BioSciences with a $2.38 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRRK:
- Scholar Rock reports Q3 EPS (53c), consensus (52c)
- Scholar Rock presents new data from Phase 1 DRAGON trial
- Scholar Rock participates in a conference call with Jefferies
- Jefferies upgrades ‘off-the-radar small cap’ Scholar Rock to Buy ahead of data
- Scholar Rock upgraded to Buy from Hold at Jefferies
